Rigel Pharmaceuticals, Inc. (RIGL) Q4 FY25 Earnings Call

Strong portfolio growth and cash generation continue, but 2026 growth normalizes while R289 remains an early clinical catalyst [69][113].

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-03-04
Length51 minutes
EPS$1.14
EPS consensus$1.33
Revenue$69.5M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26

All RIGL earnings ยท Back to RIGL overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.